May 15, 2024
Cell and gene therapies (CGT) represent the future of precision medicine, offering the potential to improve patient outcomes across a range of diseases. However, bringing these complex therapies from bench to bedside presents unique challenges at every stage of development. As the CGT landscape continues to evolve rapidly, developers need an experienced partner who can provide integrated solutions to overcome key hurdles at every stage from early research through commercialization. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Franklin, PhD, vice president and enterprise head of CGT at Labcorp, shared how Labcorp’s comprehensive CGT capabilities support all aspects of global CGT development, including preclinical pharmacology, companion diagnostics (CDx) development and validation.